D Dimer Testing Market Analysis, Demand And Outlook 2025- 2034

Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Current Size and Annual Growth Rate of the D Dimer Testing Market?
The d dimer testing market size has grown steadily in recent years. It will grow from $1.47 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to the emergence of thrombosis research, improvements in laboratory techniques, clinical validation of d-dimer as a marker, and a shift in diagnostic protocols.

The d dimer testing market size is expected to see strong growth in the next few years. It will grow to " $1.9 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to the increasing geriatric population, growth in point-of-care testing (POCT), integration with risk assessment algorithms, increased awareness and education campaigns, regulatory guidance and standardization. Major trends in the forecast period include biomarker combinations for enhanced diagnosis, focus on rapid and accurate results, d-dimer testing in COVID-19 management, remote monitoring and home-based testing kits, continuous monitoring, and serial testing.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12341&type=smp

What Are the Primary Factors Driving the D Dimer Testing Market?
The increasing prevalence of cancer is expected to propel the growth of the d-dimer testing market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. D-dimer testing is primarily used to help diagnose, monitor, and treat cancer patients and assess the risk of blood clot formation. It monitors thrombotic events in various clinical settings. For instance, in January 2022, according to research published by the American Cancer Society, a US-based health organization, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in the US in 2022. It is about 1,670 fatalities each day. Therefore, the increasing prevalence of cancer is driving the growth of the d-dimer testing market.

How Is the D Dimer Testing Market Categorized Based on Key Segments?
The d dimer testingmarket covered in this report is segmented –

1) By Test: Clinical Laboratory Tests; Point-Of-Care Tests
2) By Product: Analyzers; Reagents And Consumables
3) By Method: Enzyme-linked Immunosorbent Assay (ELISA); Latex-enhanced Immuno-turbidimetric Assays; Fluorescence Immunoassays; Other Testing Method
4) By Application: Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Disseminated Intravascular Coagulation (DIC); Other Application
5) By End-User: Hospitals; Academic And Research Institutes; Diagnostic Centers; Other End-User

Subsegments:
1) By Clinical Laboratory Tests: Enzyme-Linked Immunosorbent Assay (Elisa); Chemiluminescent Immunoassay (CLIA); Latex Agglutination Assays; Other Laboratory Testing Methods
2) By Point-Of-Care Tests: Rapid Test Kits; Portable Testing Devices; Lateral Flow Assays; Other Point-Of-Care Testing Methods


What New Market Trends Are Emerging in the D Dimer Testing Market?
Major companies operating in the D-dimer testing market are adopting a strategic partnership approach to gain exclusive rights to D-dimer testing solutions and gain a competitive edge in the market. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in March 2022, SphingoTec GmbH, a Germany-based biotechnology company, partnered with Rivaara Labs Pvt Ltd., an India-based medical laboratory and healthcare company. Under this partnership, Rivaara gains exclusive rights to market and distribute SphingoTec's point-of-care tests featuring innovative biomarkers in the Indian subcontinent. These biomarkers encompass proenkephalin (penKid) for kidney function assessment, bioactive adrenomedullin (bio-ADM) for endothelial function evaluation, and dipeptidyl peptidase 3 (DPP3) as a biomarker for cardiac depression. These pioneering markers are supplemented by commonly utilized parameters such as procalcitonin, troponin, D-dimer, NT-proBNP, and TSH.

Who Are the Major Companies Operating in the D Dimer Testing Market?
Major companies operating in the D dimer testing market include Kaiser Foundation Health Plan Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Becton Dickinson And Company (BD), Laboratory Corporation, Quest Diagnostics Inc., bioMérieux SA, Beckman Coulter Inc., Quidel Corporation, QuidelOrtho Corporation, Sysmex Corporation, Horiba Ltd., Werfen SA, Helena Laboratories Corporation, Abcam plc, LumiraDx Limited, Personalabs, Sekisui Diagnostics LLC, Diagnostica Stago S.A.S., RayBiotech Inc., CTK Biotech Inc., Diazyme Laboratories Inc., AdvaCare Pharma USA, UCP Biosciences Inc., AccuBioTech Co Ltd., Response Biomedical Corporation

Get the detailed d dimer testing market report today
https://www.thebusinessresearchcompany.com/report/d-dimer-testing-global-market-report

Which Region Holds the Largest Share of the D Dimer Testing Market?
North America was the largest region in the D dimer testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the D dimer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company